The complications of LN result from the pathophysiology intrinsic to the glomerular disease, including hypertension, nephritic and nephrotic syndromes, and renal failure, as well as from side effects of treatment. While clinicians treating patients with LN have traditionally focused on therapeutic interventions to reduce the risks of renal failure, there is emerging appreciation that treatment may be required to interdict the cardiovascular and thromboembolic complications engendered by protracted nephrotic syndrome. Indeed, evidence of the benefit of achieving even partial remission of proteinuria (to the subnephrotic level) has a salutary effect on patient and renal survival. Beyond standard immunosuppressive therapies, the full armamentarium of renal protection strategies, particularly angiotensin antagonists and lipid-lowering statin drugs, is warranted in management of LN.